

Original Research Article

EVALUATION OF THE PHARMACOLOGICAL REPOSITIONING OF THIOCOLCHICOSIDE AS AN ANTIBACTERIAL DRUG

Abstract

Pharmacological repositioning has been increasingly praised as a viable, low-cost and rapid alternative for the development of a new therapy for clinical application, such as cases of bacterial resistance. Therefore, the present study aimed to investigate the antibacterial action of the myorelaxant thiocolchicoside against bacterial strains. For this, an in vitro experimental study was developed using the bacterial strains *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Proteus mirabilis* ATCC 25933 and *Pseudomonas aeruginosa* ATCC 27853, and the protocols: antibacterial activity screening, Minimum Inhibitory Concentration (MIC) and characterization of antibacterial activity. The substance was thiocolchicoside, in concentrations ranging from 0.48 to 1000 µg/mL. Low sensitivity of bacterial strains to the myorelaxant was observed, obtaining an MIC of 500 µg/mL for *E. coli* and 1000 µg/mL for *P. aeruginosa*, the only strains sensitive to the compound. In the antibacterial activity characterization test, thiocolchicoside showed bacteriostatic action. Thus, although this drug is already safe for human use, no significant antimicrobial effects were observed in standard bacterial strains. Thus, studies are needed on its action in comparison with other microorganisms, such as other bacterial species, fungi and protozoa, in order to exclude its possibility as a viable antibiotic substance for commercial use.

Keywords: antibacterial activity; bacterial resistance; pharmacological repositioning, thiocolchicoside.

Introduction

The repositioning of drugs, which consists of applying a drug that is already known and commercialized in a new clinical context, arises from the glimpse of the pleiotropic effects of some drugs and the need for increasingly effective pharmacological alternatives for clinical practice. In this scenario, how advantages of this route that can be exalted are the lower cost and prior knowledge about toxicological aspects in the human body (Brandão et al., 2022). To illustrate this context, mention should be made of HMG-CoA reductase inhibitors and their potential for neuroprotection and sepsis management (Almeida et al., 2020).

The growing increase in bacterial drug resistance is a worrying issue in the context of global health. The exacerbated and inconsequential application of antibiotic therapy is identified as the main cause of this problem (Aljeldah 2022; Loureiro et al., 2016). In view of the above, there is a need for new antibacterial pharmacological therapies and drug reuse seems to be a viable, fast and less costly strategy when compared to standard drug development (Miethke et al, 2021; Pereira, Oliveira, 2016). It is also extolled that during the COVID-19 pandemic this device was more discussed, however, the first article on this topic was published by (PPD, 2003), Ashburn and Thor, and the number of articles increased after Langedijk et al. (2015).

Thus, considering the urgency in the search for new antibacterial therapies, the increasing identification of drug-resistant strains and the increase

in complications due to infectious conditions, the need for further studies from the perspective of drug reuse is justified. Therefore, this study aims to investigate the action of the myorelaxant thiocolchicoside against bacteria, raising the possibility of a new antimicrobial agent.

METHODOLOGY

Search location:

The tests were carried out in the Microbiology laboratory of the Teacher Training Center (CFP) of the Federal University of Campina Grande (UFCG), Cajazeiras campus.

Substances used

To carry out the experiments, an injectable thiocolchicoside solution (Sanofi Aventis®) of 2mg/ml was used as the target of the investigation. Sterile distilled water, gentamicin as diluent and control group were also used, respectively.

Microorganisms

The sensitivity of four standard American Type Culture collection (ATCC) bacterial strains was evaluated: *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Proteus mirabilis* ATCC 25933 and *Pseudomonas aeruginosa* ATCC 27853. The culture media used were Mueller-Hinton Agar (MHA), Müller-Hinton Broth (MHB) and BHI Broth (Brain Heart Infusion Broth) (KASVI).

Bacterial inoculum

The bacteria were previously incubated in sterile BHI broth and placed in an oven for 24 hours at $35 \pm 2^\circ\text{C}$. After this period, the suspension was seeded

on petri plates containing sterile Mueller Hinton Agar using the streak depletion method and incubated again for another 24 hours. Small volumes of the formed bacterial suspension were collected and inserted and homogenized in a tube containing sterile saline for the administration of 0.5 McFarland turbidity (1×10^8 CFU / mL), being verified with the aid of a turbidimeter.

Screening for antibacterial activity

The principle followed for the disk-diffusion method consists of applying a paper filter with bacterial solution at different concentrations on the agar. For this purpose, 6mm diameter discs received according to the following concentrations of the test substance: 2000, 1000, 500, 250, 125 $\mu\text{g/mL}$; distilled water, in a volume of 10 μL of solution. Also, disks containing the commercial antimicrobial (ATM) GEN - Gentamicin 10 μg (CECON) were considered as a positive control.

The bacterial inoculum was applied to the surface of the agar with the aid of a sterile swab and spread on the petri dish four times at a 45° angle, rotating the plate several times at an angle of 60° and ending with the contour on the edges of the agar. With the aid of sterilized tweezers, the previously treated disks were adjusted on the plate. The experiments were carried out in triplicate and conserved in an oven for 24 hours at 35°C .

Minimum Inhibitory Concentration

Microdilution was performed in a 96-well plate, with the aid of sterilized pipettes and tips. In all wells, 100 μL of Mueller-Hinton broth was added. For the dilution of the test substance, 100 μL of the solution was discarded and homogenized in the first well and 100 μL removed for the next well. This process was carried out in all wells of lines A, B and C, obtaining the following

concentrations: 1000; 500; 250; 125; 62.5; 31.25; 15.62; 7.8; 3.9; 1.9; 0.9; 0.48 µg/mL.

This sequence was repeated in well E, for the standard antibiotic. After that, 10 µL of bacterial inoculum was added. Sterility control and the test with only the diluent (distilled water) were performed. The plates were kept in an oven at a temperature of 35°C for 24 hours. The reading occurred through the colorimetric assay with 20 µL of sodium resazurin solution (0.01%; w/v) (SIGMA).

Characterization of Antibacterial Activity

The definition of antibacterial activity was met by sowing, in Müller-Hinton Agar, 10µL aliquots of the dilutions corresponding to the MIC and two immediately higher (2xMIC and 4xMIC), when possible, of the contents of the wells of the microdilution plates. These concentrations immediately above the MIC are sufficient to demonstrate whether the activity shown by the substance is bactericidal or bacteriostatic, with the bacteriostatic effect being evidenced when there is bacterial growth in the microdilution plate wells delimited previously (Farias et al, 2020).

After sowing, the plates will be incubated in a bacteriological oven at 35 ± 2°C for 24 hours. The Minimum Bactericidal Concentration (MBC) will be considered the lowest concentration that prevents the visible growth of bacteria or allows the formation of up to three Colony Forming Units (CFU). The experiments will be performed in triplicate.

Statistical analysis

All experiments were performed in triplicate. The results were approved for statistical treatment using GraphPad Prism® 5.0 software (GraphPad

Software, Inc., San Diego, CA). The data obtained were subjected to analysis of variance (ANOVA) and expressed as mean \pm standard deviation. Differences were evaluated using the paired t-test and were calculated when $p < 0.05$.

RESULTS

Antibacterial screening

In screening for antibacterial activity, the formation of a microbial growth inhibition halo was not observed for any of the bacterial strains used in the study (Table I).

Strains	Diameter of the Growth Inhibition Halo (mm)					Gentamicin 30 μ g	*C
	Thiocolchicoside (μ g/mL)						
	2000	1000	500	250	125		
<i>Staphylococcus aureus</i> ATCC 25923	U [#]	U [#]	U [#]	U [#]	U [#]	22	U [#]
<i>Escherichia coli</i> ATCC 25922	U [#]	U [#]	U [#]	U [#]	U [#]	17	U [#]
<i>Proteus mirabilis</i> ATCC 25933	U [#]	U [#]	U [#]	U [#]	U [#]	20	U [#]
<i>Pseudomonas aeruginosa</i>	U [#]	U [#]	U [#]	U [#]	U [#]	22	U [#]

Table I: Diameter of bacterial growth inhibition zones for thiocolchicoside, gentamicin and control against strains *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Proteus mirabilis* ATCC 25933 and *Pseudomonas aeruginosa* ATCC 27853 strains.

*C – solvent/diluent control: Discs impregnated with a solution of DMSO (10%) and Tween 80 (2%); #U: it was not possible to visualize the formation of a halo of inhibition of bacterial growth at the concentration of the substance used in the dif-disc method.

As a method control, the antibiotic gentamicin was used, where the formation of growth inhibition zones was evidenced for the strains *S. aureus* ATCC 25923, *E. coli* ATCC 25922, *P. mirabilis* ATCC 25933 e *P. aeruginosa* ATCC 27853 in the amount 22mm, 17mm, 20mm and 22mm respectively. A solution with DMSO and Tween 80 was used as a negative control, where no halo formation of microbial growth inhibition was observed.

Minimum inhibitory concentration

The strains *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853 showed some sensitivity vis-à-vis the myorelaxant, when they drank the testicles of midrodilution, with a minimum inhibitory concentration of 500µg/mL and 1000 µg/mL, respectively. The results can be seen in Table II.

Table II: MIC and MBC values for thicolchicoside and gentamicin against *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Proteus mirabilis* ATCC 25933 and *Pseudomonas aeruginosa* ATCC 27853 strains

Strains	Thicolchicoside			Gentamicin	*C ₁	**C ₂	***C ₃
	MIC	Effect	MBC	(µg/mL) MIC			
<i>Staphylococcus aureus</i> ATCC 25923	+	U [#]	U [#]	<1	+	-	+
<i>Escherichia coli</i> ATCC 25922	500	Bacteriostatic	U [#]	1	+	-	+
<i>Proteus mirabilis</i> ATCC 25933	+	U [#]	U [#]	16	+	-	+
<i>Pseudomonas aeruginosa</i> ATCC 27853	1000	Bacteriostatic	U [#]	<1	+	-	+

*C₁ – microbial growth control: wells containing mueller-hinton broth and bacterial inoculum, in the absence of DMSO (10%), Tween 80 (2%), thicolchicoside or gentamicina; **C₂: Culture medium sterility control: wells containing mueller-hinton broth, in the absence of bacterial inoculum, DMSO (10%), Tween 80 (2%), thicolchicoside or gentamicina; ***C₃ – solvent/diluent control: wells containing mueller-hinton broth, DMSO (10%), Tween 80 (2%) and bacterial inoculum, in the absence of thicolchicoside or

gentamicina; #U: Indeterminate for thiocolchicoside concentrations used in the assay; (-): inhibition of bacterial growth; (+): presence of bacterial growth; MIC: Minimum Inhibitory Concentration; CBM: Minimum Bactericidal Concentration.

The results of the other strains in the microdilution test are shown in the Table II, for *P. mirabilis* and *S.aureus*, with resazurin redox reaction being observed in all wells destined to the test drug, indicating biological activity of the microorganism.

Characterization of antibacterial activity

The characterization of the antibacterial activity demonstrated by thiocolchicoside was performed for drug-sensitive strains, *P. aeruginosa* and *E. coli*, after microdilution assays.

For this, aliquots of the wells corresponding to the concentrations of MIC, 2 x MIC and 4 x MIC (limited to the highest concentration of 1,000 µg/mL) were seeded and incubated under favorable conditions for 24 hours. Thus, it was observed that, in all concentrations used, there was abundant bacterial growth in the plate with culture medium, characterizing the antibacterial effect presented by the test substance as bacteriostatic (Table II).

DISCUSSION

Thiocolchicoside is a myorelaxant derived from the alkaloid colchicine, and is used as a myorelaxant, with potential for pharmacological repositioning, especially in oncology. Studies suggest an ability to suppress osteoclastogenesis induced by breast cancer and multiple myeloma cells, as well as an anticancer effect through the downregulation of the NF-κB pathway and its gene products (Reuter et al, 2012, Reuter et al, 2010).

However, until now, there is no knowledge of researches in bacteriology that investigate the potential of thiocolchicoside. As the safety of this drug in clinical practice is public knowledge, it is interesting to investigate its potential against bacteria. Due to the current scenario of dissemination of bacterial infections in world societies, especially in poorer countries, the use of antibiotics is increasing and sometimes inconsequential, which is causing and expanding bacterial resistance (Llor; Bjerrum, 2014).

Some drugs, such as acetylsalicylic acid (ASA) and fluoxetine, already have antibacterial action explored in the scientific literature. Lee et al. (2014) suggest that the in vitro antibacterial activity of ASA occurs from the decrease in bacterial production of polysaccharides, affecting the growth of these microorganisms. Fluoxetine has an in vitro inhibitory effect of 256 and 102 µg/mL against standard and resistant strains of *S. aureus*, respectively. Against standard and resistant strains of *P. aeruginosa* it was 161 µg/mL and against *E. coli*, the MIC of fluoxetine was 102 µg/mL (Sousa et al.,2018).

The data obtained in this investigation bring to light the perspective of muscle relaxants from the point of view of antibiotic therapy. There is no previous information described in the literature about thiocolchicoside against bacterial strains in vitro, and this study demonstrated a weak antibacterial activity against the investigated strains. Thus, these results will guide future research from the point of view of repositioning drugs for new therapies against infectious agents.

Although this drug has cytotoxic action, no significant antibacterial effect was observed on the ATCC strains used in the study, but studies are still

needed on its action against other microorganisms, such as other bacterial species, fungi and protozoa. [15].

REFERENCES

ALJELDAH MM. 2022. Antimicrobial Resistance and Its Spread Is a Global Threat. *Antibiotics*. 11: 1082.

ALMEIDA HMDS; RAMOS ACA; FERREIRA SB. 2020. Correlation between the use of statins and the prevention and prognosis of patients with sepsis. *Rev. Inter.* 7:497-509.

BRANDÃO LBSet al. 2023. Progress and Understandings in the Pharmacological Repositioning Scenario. *European journal of medical and health sciences*. 5:28–31.

FARIAS TC et al. 2020. “Modulative and adaptive effect of (+)-alpha-pinene in front of commercial antimicrobials in *Staphylococcus aureus* strains”, *International Journal of Development Research*, 10: 33594-33600.

LANGEDIJK J. et al 2015. Drug repositioning and repurposing: terminology and definitions in literature. *Drug Discovery Today*. 20: 1027–1034.

LEE CH. 2014. Aspirin increases opsonophagocytosis and is associated with a lower risk of invasive *Klebsiella syndrome pneumoniae*. *BMC Dis infection*. 30: 14-47.

LLOR C, BJERRUM L. 2014. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf*. 5:229-41.

LOUREIRO RJ et al. 2016. O uso de antibióticos e as resistências bacterianas: breves notas sobre a sua evolução. *Rev. Port. Sau. Pub.*34: 77-84.

MIETHKE M et al. 2021. Towards the discovery and sustainable development of new antibiotics. *Nat Rev Chem*. 5: 726–749.

PEREIRA EL, OLIVEIRA AFA. 2016. A produção de antibióticos por processos fermentativos aeróbios. *Rev Univ Vale do Rio Verde*. 14: 1058- 78.

PPD 2003. PPD acquires Lilly's patents for dapoxetine; adjusts earnings guidance for 2003 [online PPD press release].

REUTER S et al. 2010. Thiolcolchicoside exhibits anticancer effects through downregulation of NF- κ B pathway and its regulated gene products linked to inflammation and cancer. *Cancer Prev Res*. 3:1462–1472.

REUTER S et al. 2012. Thiolcolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. *British journal of pharmacology*. 165: 2127–2139.

SOUSA AK et al. 2018. New roles of fluoxetine in pharmacology: Antibacterial effect and modulation of antibiotic activity. *Microbial Pathogenesis*. 123: 368–371.

YOON S, KIM HS. 2021. Repositioning of Drugs with Anticancer Effect: Contributions to Reducing the Incidence of Cancer in Susceptible Individuals. *In Vivo*. 35: 3039–3044.